ClinicalTrials.gg
RecruitingNCT07603960CHILL-EndoUpdated May 22, 2026

Whole-Body Cryotherapy as a Non-Pharmacological Treatment to Reduce Chronic Pelvic Pain and Improve Quality of Life in People With Endometriosis

An interventional study of Whole-Body Cryotherapy in Endometriosis, sponsored by University of Edinburgh. Recruiting at 1 site in United Kingdom. Open to female participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by University of Edinburgh · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
16 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Endometriosis with a site in United Kingdom — 10 open to participants now, 11 under way, none of them phase 3. Endometriosis · United Kingdom.

Planned enrollment
9th of 13
30 · median 50
Started
2026
with 1 other
No phase
6 of 25
2 open now
Primary completion
2026-11
later than 3 of 10 live
Registered
25th of 25
by date
Lead sponsor
6 of 25
University of Edinburgh

Among the 25 studies in Endometriosis with a site in United Kingdom, this one is the 9th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2026, is one of 6 with no phase, reaches primary completion later than 3 of the 10 other live ones, and was the 25th registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

10 of the 25 studies in Endometriosis with a site in United Kingdom are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 16 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Endometriosis with a site in United Kingdom, or all of them as a file.
02

Study summary

The aim of this study is to investigate whether whole-body cryotherapy (a brief exposure to very cold temperatures) can help reduce pain and improve quality of life in people living with endometriosis, and whether it may represent a safe, non-pharmacological approach to managing endometriosis-related symptoms.

Up to 30 participants with symptomatic endometriosis (chronic pelvic pain for more than six months) will be recruited over a 12-month period. Participants will attend two study visits at the hospital, approximately four weeks apart. Between these visits, participants will undergo five whole-body cryotherapy sessions, each lasting approximately 3 minutes. During cryotherapy, participants stand in a specialised chamber where the body is briefly exposed to cold, dry air (around -120°C).

During the study, will be assessed changes in systemic inflammation and biological markers using blood, saliva, urine, vaginal, and stool samples. Data will be collected using questionnaires evaluating pain and related symptoms, quality of life, sleep, fatigue, intestinal symptoms, and overall wellbeing.

The active study phase lasts approximately 4-6 weeks. A final follow-up assessment at 15 weeks will be conducted remotely using questionnaires and self-collected samples.

Read the detailed description

Endometriosis is a chronic inflammatory and estrogen-dependent condition characterized by the presence of endometrial-like tissue outside the uterus, commonly associated with persistent pelvic pain, reduced quality of life, and significant long-term morbidity. Despite available hormonal and surgical treatments, a substantial proportion of individuals continue to experience chronic pain, highlighting an unmet need for novel therapeutic approaches. Current treatment strategies do not fully address the underlying inflammatory, neurovascular, and nociceptive mechanisms that contribute to pain persistence and central sensitization in endometriosis.

Whole-body cryotherapy (WBCT) is a non-pharmacological intervention involving brief exposure to extremely low temperatures, which has been associated with anti-inflammatory, analgesic, and neuromodulatory effects in other chronic conditions. Proposed mechanisms include modulation of systemic inflammatory pathways, reduction of oxidative stress, and effects on central pain processing. However, the potential role of WBC in the management of endometriosis-associated pain has not yet been established.

This study is a single-site, single-arm interventional pilot study designed to evaluate the feasibility, safety, acceptability, and preliminary efficacy of a structured WBCT intervention in individuals with symptomatic endometriosis. In addition to clinical outcomes, the study aims to explore biological mechanisms underlying potential treatment effects through the assessment of systemic inflammatory and other biomarkers.

Participants will undergo a standardized course of WBCT sessions over a two-week period, with repeated clinical and biological assessments conducted at predefined timepoints. Clinical outcomes will include patient-reported measures of pain, quality of life, fatigue, sleep, and other symptom domains, as well as analgesic use and global impression of change. Feasibility outcomes will include recruitment rates, retention, and participant acceptability of the intervention and study procedures.

Biological assessments will include the collection of blood (venous and capillary), saliva, urine, vaginal, and stool samples to evaluate markers of systemic inflammation, stress, and gut health. Samples will be collected at baseline, during the intervention period, and at follow-up, enabling exploration of temporal changes associated with WBC exposure.

Study visits will be conducted at baseline and post-intervention, with an additional remote follow-up evaluation. The intervention phase includes multiple WBC sessions delivered at a dedicated facility, with complementary data collection performed both in-clinic and through self-collected samples.

The findings from this exploratory study will provide preliminary evidence on the clinical and biological effects of WBCT in endometriosis, inform the feasibility of larger controlled trials, and contribute to understanding whether WBCT may represent a novel non-pharmacological approach targeting inflammatory and nociceptive pathways in endometriosis-associated pain.

03

Conditions studied

  • Endometriosis

Keywords

  • endometriosis
  • cryotherapy
  • inflammation
  • pain
  • chronic pelvic pain
  • endometriosis-associated pain
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women or assigned female at birth
  • Aged 16 or over
  • Endometriosis identified at laparoscopy or imaging, performed within the last ten years
  • Chronic pelvic pain for more than six months
  • Willing to comply with the treatment
  • Willing to use effective throughout the trial (if needed)
  • Willing and able to give

Exclusion criteria

Exclusion Criteria:

  • Pregnant, breastfeeding or actively trying to get pregnant
  • (no periods for >12 months and not taking hormonal treatments to prevent periods, or bilateral oophorectomy performed)
  • Previous hysterectomy with bilateral oophorectomy
  • Raynaud's Disease
  • Current treatment for
  • Diabetes
  • Known hypothyroidism
  • Pre-existing or current diagnosis of anaemia
  • Cardiovascular disease: severe hypertension (180/100, unstable angina, arrhythmia, recent (\<6months) myocardial infarction, peripheral artery disease, cardiac pacemaker, recent (\<6months) stroke or )
  • Acute kidney and urinary tract diseases
  • Cryoglobulinemia
  • Previous venous thromboembolism or peripheral artery occlusive disease
  • Cold urticaria
  • Livedo reticularis
  • Open wounds or ulcers, large-area bacterial and viral skin infections
  • Uncontrolled seizure disorder
  • Known coagulopathy (eg von Willibrand disease, haemophilia)
  • Severe claustrophobia
  • Acute infections and fever
  • Intoxication (alcohol, drugs)
  • Signs or symptoms of cold allergy
  • Severe wasting diseases
  • Known /C and/or (due to Royal Mail restrictions on biospecimen postage)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Whole-Body Cryotherapy in Endometriosis

    Participants with symptomatic endometriosis will undergo a structured course of whole-body cryotherapy consisting of five sessions over approximately two weeks. Each session involves brief exposure (approximately 3 minutes) to extremely cold, dry air (around -120°C) in a specialised cryotherapy chamber. Clinical and biological assessments will be conducted before and after the intervention period.

    Procedure: Whole-Body Cryotherapy

Interventions

  • ProcedureWhole-Body Cryotherapy

    Whole-body cryotherapy is a non-pharmacological intervention involving brief exposure of the body to extremely cold, dry air (typically around -110°C to -140°C) in a specialised cryotherapy chamber. Each session lasts approximately 2-3 minutes and is conducted under controlled conditions. The intervention is designed to induce physiological responses including vasoconstriction, modulation of inflammatory pathways, and potential analgesic effects.

    Also known as: WBCT

06

What researchers measure

Primary outcomes

  1. Change in average pain over the preceding week measured by an 11-point Numerical Rating Scale (NRS)

    The Numerical Rating Scale (NRS) ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst possible pain. Participants will rate their average pain over the preceding week at baseline and at 4 weeks following completion of the cryotherapy intervention.

    Time frame: From baseline to 4 weeks post-intervention

Secondary outcomes

  1. Change in average pain over the preceding week measured by an 11-point Numerical Rating Scale (NRS)

    The Numerical Rating Scale (NRS) ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst possible pain. Participants will rate their average pain over the preceding week at baseline and at 15 weeks.

    Time frame: From baseline to 15 weeks

  2. Change in neuropathic pain assessed by the PainDETECT questionnaire (PD-Q)

    The PainDETECT questionnaire (PD-Q) is a validated 9-item screening tool used to assess neuropathic pain components. Scores range from -1 to 38, with higher scores indicating a higher likelihood of neuropathic pain.

    Time frame: From baseline to 4 weeks and 15 weeks

  3. Change in quality of life assessed by Endometriosis Health Profile (EHP-30)

    The Endometriosis Health Profile (EHP-30) questionnaire is a validated tool used to assess quality of life components over the previous four weeks. It includes 30 core questions (five scales: pain, control, emotions, social support, self-image) scoring 0-100, where higher scores indicate worse health.

    Time frame: From baseline to 4 weeks and 15 weeks

  4. Change in health-related quality of life assessed by EQ-5D-5L questionnaire

    The EQ-5D-5L questionnaire is a validated 5-level tool used to measure health-related quality of life, consisting of a descriptive system covering five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and a vertical visual analogue scale (VAS) ranging from 0 (worst) to 100 (best).

    Time frame: From baseline to 4 weeks and 15 weeks

  5. Change in severity of fibromyalgia symptoms assessed by Fibromyalgia Impact questionnaire

    The Fibromyalgia Impact questionnaire is a validated tool used that measure the severity of fibromyalgia, its impact on daily life, and treatment progress. Scores range from 0 to 100, where higher scores indicate greater impairment. A score of 50 indicates an average patient, while over 70 indicates severe impairment.

    Time frame: From baseline to 4 weeks and 15 weeks

  6. Change in fatigue assessed by the Fatigue Severity Scale (FSS)

    The Fatigue Severity Scale (FSS) questionnaire is a 9-item self-report questionnaire designed to measure the severity of fatigue and its impact on daily functioning, particularly for chronic conditions. Respondents rate statements on a 7-point Likert scale (9-63), with higher scores (up to 63) indicating greater fatigue severity.

    Time frame: From baseline to 4 weeks and 15 weeks

  7. Change in sleep quality assessed by the Sleep Timing Questionnaire (STQ)

    The Sleep Timing Questionnaire (STQ) is a 18-item, self-report tool used to measure habitual bedtimes, wake times, sleep latency, and wake after sleep onset (like a sleep diary).

    Time frame: From baseline to 4 weeks and 15 weeks

  8. Change in analgesic use during the study period

    Participant-reported frequency and quantity of analgesic use.

    Time frame: From baseline to 4 weeks and 15 weeks

  9. Feasibility assessed by recruitment and retention rates

    Proportion of eligible participants enrolled and completing study follow-up

    Time frame: Frome baseline to study end. Up to 12 months

  10. Patient satisfaction assessed by Patient Global Impression of Change (PGIC) questionnaire

    The Patient Global Impression of Change (PGIC) is a 7-point, self-reported scale used in clinical practice to evaluate a patient's overall perception of improvement following the intervention. Patients select one of the following to describe their change: 1. Very Much Improved 2. Much Improved 3. Minimally Improved 4. No Change 5. Minimally Worse 6. Much Worse 7. Very Much Worse

    Time frame: At 4 weeks and 15 weeks

  11. Acceptability of the intervention assessed by a study-specific questionnaire

    Overall acceptability will also be evaluated using a study-specific questionnaire assessing participant satisfaction (e.g. perceived effectiveness, and self-efficacy) with the intervention and study procedures.

    Time frame: At 4 weeks and 15 weeks

  12. Change in cognitive symptoms (brain fog) assessed by the Brain Fog Scale (BFS)

    The Brain Fog Scale (BFS) is a validated, self-report questionnaire designed to measure the severity of "brain fog" (cognitive difficulties such as memory impairment, lack of focus, and mental confusion and fatigue). It consists of 9 items rated on a 7-point Likert scale, with higher scores indicating greater symptom severity.

    Time frame: From baseline to 4 weeks and 15 weeks

  13. Change in gastrointestinal symptoms assessed by the Irritable Bowel Syndrome Symptom Severity Score (IBS-SSS)

    The IBS Symptom Severity Scale (IBS-SSS) is a 5-item, 500-point questionnaire used to measure the intensity of Irritable Bowel Syndrome symptoms over the past 10 days. It evaluates pain severity/frequency, bloating, bowel habit dissatisfaction, and quality of life, categorizing IBS as "no symptoms" (\<75), "mild" (75-174), "moderate" (175-299), or severe (300-500).

    Time frame: From baseline to 4 weeks and 15 weeks

  14. Change in systemic inflammatory markers with cortisol concentration

    Includes serum and salivary cortisol measured in blood and saliva samples, reported in µg/dL (or nmol/L)

    Time frame: From baseline to 4 weeks after cryotherapy sessions and 15 weeks

  15. Change in salivary alpha-amylase activity

    Includes salivary alpha-amylase measured in saliva samples, reported in U/mL

    Time frame: From baseline to 4 weeks after cryotherapy sessions and 15 weeks

  16. Change in systemic inflammatory markers with C-reactive protein (CRP) concentration

    Includes serum C-reactive protein (CRP) levels in blood samples, reported in mg/L.

    Time frame: From baseline to 4 weeks after cryotherapy sessions and 15 weeks

  17. Change in systemic inflammatory markers with inflammatory cytokine concentrations

    Includes inflammatory cytokines (e.g., IL-6, TNF-α, IL-1β) measured in serum/plasma samples, reported in pg/mL.

    Time frame: From baseline to 4 weeks after cryotherapy sessions and 15 weeks

  18. Change in bowel inflammatory markers with faecal calprotectin concentration

    Includes faecal calprotectin measured in stool samples, reported in µg/g.

    Time frame: From baseline to 4 weeks after cryotherapy sessions and 15 weeks

  19. Change in gut microbiome composition

    Includes gut microbiome composition assessed in stool samples.

    Time frame: From baseline to 4 weeks after cryotherapy sessions and 15 weeks

07

Study locations

1 of 1 sites recruiting
  • Institute for Regeneration and Repair, University of Edinburgh and Royal Infirmary of Edinburgh
    Edinburgh, Scotland EH16 4UX, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Requests for anonymised data sharing will be considered on a case by case basis by the trial management team with appropriate data sharing contracts in place.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Nov 2026, 7 months after the start.

Of 199 non-industry interventional studies with no phase under Endometriosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 44. This study's planned 7 months is below that.

Counting every sponsor, half of 214 studies reached it within 25 months; a quarter within 13 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 22, 2026
StartActual
Apr 9, 2026
Primary completionEst.
Nov 2026
CompletionEst.
May 31, 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07603960
Collaborators
NHS Lothian
Responsible party
Sponsor
First posted
May 22, 2026
Start date
Apr 9, 2026
Primary completion
Nov 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
May 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion